Posts

"A Bit of a Surprise": Kardigan's Tonlamarsen Shows No Blood Pressure Benefit from Repeat Dosing in Phase 2 Trial

AstraZeneca Makes Strong Case for Baxdrostat with Detailed 24-Hour Data in Resistant Hypertension Trial